The number of biopharmaceutical company initial public offerings in the US this year is just one away from the 2016 total of 30 drug developer IPOs – and with returns from newly public companies rising, 2017 could surpass last year by a sizeable margin.
With offerings by Deciphera Pharmaceuticals Inc., Nightstar Therapeutics Ltd. and NuCana BioMed Ltd. on Sept. 27, there...






